Dr. Caroline Barelle, CEO of Elasmogen, is shortlisted as one of 3 finalists in the Academic to Entrepreneur of the Year category. This category recognises an individual who has demonstrated an enterprising approach to developing and delivering enterprise and...
Our CEO Caroline Barelle was interviewed by Scottish Business News Network. In her interview, Caroline discusses the journey of starting up Elasmogen and provides an insight into the ups and downs of those early days alongside a glimpse into where Elasmogen is now and...
£2M joint program receives grant to support research into next generation technology Craigavon, N.I., UK, 6 Aug 2018 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and...
17th May 2018: Aberdeen, Scotland: Elasmogen Ltd, developer of soloMERTM biologics, today announced that Dr Caroline Barelle was named as the winner in the “Rising Stars: Extraordinary Talent (2017)” category at last night’s Scotland’s Life Sciences Dinner &...
Dr. Caroline Barelle (CEO) has been selected as a finalist for the Rising Stars: Extraordinary Talent Award. Some of Scotland’s most dynamic life sciences companies and business leaders have been shortlisted for the prestigious Scottish Life Sciences Awards 2018. Read...
Elasmogen’s CEO Dr Caroline Barelle has been named in Labiotech.eu’s list of top female entrepreneurs. Read the article here.
Combined Feldan Shuttle and Elasmogen soloMER technology will be used to deliver intracellular candidates for two targets Aberdeen, Scotland and Quebec City, Canada; 9 May 2017: Elasmogen Ltd, focused on the development of next generation biologics, and Feldan...
Funding from Deepbridge Capital, Innovate UK and Scottish Investment Bank will support development of next generation Ophthalmology biologics Thursday, 16 March 2017: Aberdeen, Scotland: Elasmogen Ltd, developer of soloMERTM biologics, today announced that it has...
BBSRC support for research and commercialisation contributed to the creation of award-winning spin-out company Elasmogen by Dr Caroline Barelle and Professor Andrew Porter at the University of Aberdeen. The company is developing new medicines based on the discovery of...
Aberdeen, UK – [July 2016] OBN announced recently the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic Biology and Digital Health. The OBN Awards remain independent and celebrate innovation across the UK life sciences industry and recognise...
Aberdeen, UK – [27th March 2016] As Europe's leading biopartnering and investment conference, BioTrinity brings together investors, pharmaceutical executives and innovative life science R&D companies, from around the world. To mark BioTrinity’s 10th anniversary...